Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Blood Coagul Fibrinolysis. 2023 Oct 27;34(8):499–507. doi: 10.1097/MBC.0000000000001258

Table 3:

Patient outcomes by group (*note that significance is p < 0.012). (categorical variables are expressed in N (%) and numerical variables in median (interquartile range)).

Control Experimental P-value
(N=18) (N=19)
Pulmonary Embolism 3 (16.7) 0 0.1050
Pulmonary Embolism Occurrence (Hospital Day) 2, 5, 8, 12
Deep Venous Thrombosis 2 (11.1) 0 0.2297
Overall VTE 4 (22.2) 0 0.0463
Hospital days 12.5 (6.0–33.0) 14.0 (8.0–18.0) 0.8314
ICU days 5.0 (2.0–13.0) 4.0 (3.0–10.0) 0.8785
ICU free days 23.0 (15.0–26.0) 24.0 (15.0–25.0) 1.0000
Ventilation days 2.0 (0.0–6.0) 2.0 (0.0–5.0) 0.8284
Ventilator free days 26.0 (22.0–28.0) 26.0 (23.0–28.0) 0.9014
Death 0 1 (5.6) Anoxic brain injury; deemed non-preventable 1.0000